AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37936786
Drug: Brilinta® 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brilinta® 90 mg (Ticagrelor) tablet
Trial: 37937444
Drug: Immunochemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunochemotherapy with low-dose radiotherapy (LDRT) and conventionally fractionated radiotherapy (CFRT)
Trial: 37937763
Drug: Osimertinib-chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib-chemotherapy
Trial: 37938055
Drug: Blood lead
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood lead (BL) concentration measured by inductively coupled plasma mass spectrometry, baseline concentration 4.35 μg/dL, increased 3.17-fold over follow-up (median: 2.03 years; range: 0.92-6.45 years).
Trial: 37938560
Drug: Intravenous methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous methylphenidate (fast delivery)
Trial: 37938560
Drug: Oral methylphenidate
RxNorm normalized name: methylphenidate Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methylphenidate (slow delivery)
Trial: 37938561
Drug: Dendritic Cell
RxNorm normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dendritic Cell (DC) vaccines
Trial: 37938871
Drug: Group-based acceptance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based acceptance and commitment therapy (ACT), 7 sessions of 45-60 min over 4 weeks
Trial: 37939133
Drug: Intravenous nivolumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nivolumab followed by maximal safe resection and an intracerebral injection of ipilimumab alone or combined with nivolumab, biweekly adjuvant nivolumab up to five times.
Trial: 37939141
Drug: Bictegravir/emtricitabine/tenofovir alafenamide
RxNorm normalized name: Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF; 50/200/25 mg)
Trial: 37939259
Drug: Intratumoral toll-like
RxNorm normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoral toll-like receptor 9 (TLR9) agonist with local low-dose radiation and ibrutinib
Trial: 37940357
Drug: Corticosteroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid treatment (7-day course)
Trial: 37940387
Drug: Neuroform Atlas
RxNorm normalized name: LACTIC ACID 0.58 g in 100 g TOPICAL LIQUID [Atlas Prep Activator]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroform Atlas Stent System (used for treatment of proximal ICA aneurysms)
Trial: 37940387
Drug: Neuroform Atlas
RxNorm normalized name: LACTIC ACID 0.58 g in 100 g TOPICAL LIQUID [Atlas Prep Activator]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroform Atlas Stent System (used for treatment of distal anterior circulation aneurysms)
Trial: 37940433
Drug: Extended antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended antibiotic therapy (10 days of broad-spectrum antibiotics: piperacillin/tazobactam converted to amoxicillin/clavulanic acid at discharge)
Trial: 37940433
Drug: Extended antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended antibiotic therapy
Trial: 37940433
Drug: Standard perioperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard perioperative antibiotics (single dose before incision)
Trial: 37940433
Drug: Standard perioperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard perioperative antibiotics
Trial: 37940446
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg intravenously every 3 weeks plus enzalutamide 160 mg orally once daily
Trial: 37940936
Drug: Treviamet® &
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treviamet® & Treviamet XR® (Sitagliptin with Metformin)
Trial: 37941012
Drug: Stereotactic arrhythmia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic arrhythmia radioablation (STAR) with dose escalation from 27.0 Gy to a maximum of 35.1 Gy while keeping the planning target volume (PTV) dose constant at 25 Gy.
Trial: 37941012
Drug: Stereotactic arrhythmia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic arrhythmia radioablation (STAR) with dose escalation.
Trial: 37941087
Drug: Monthly social
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly social telephone call from a trained research assistant
Trial: 37941113
Drug: Clazakizumab (humanized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clazakizumab (humanized monoclonal antibody that neutralizes interleukin-6)
Trial: 37941470
Drug: Repository corticotropin
RxNorm normalized name: Repository Corticotropin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repository corticotropin injection (RCI) 80 u twice weekly for 6 months
Trial: 37941561
Drug: Neoadjuvant systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant systemic therapy (NAST)
Trial: 37941759
Drug: Hula intervention,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hula intervention, 6 months, twice per week, 60 minutes each session, plus 60 minutes of home practice per week.
Trial: 37941845
Drug: Paclitaxel-drug-coated balloon
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel-drug-coated balloon (DCB) after bare-metal stent (BMS) implantation
Trial: 37941979
Drug: Ipilimumab and
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab and nivolumab combination (10% after 2018)
Trial: 37941979
Drug: Second-line medical
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line medical treatment
Trial: 37942277
Drug: TNFi (tumor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNFi (tumor necrosis factor inhibitors)
Trial: 37942314
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) administration of AMG 212
Trial: 37942314
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous (CIV) administration of AMG 212
Trial: 37942328
Drug: 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg cadonilimab every 2 weeks plus lenvatinib (cohort A)
Trial: 37942328
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg cadonilimab every 3 weeks plus lenvatinib (cohort B)
Trial: 37942487
Drug: Dual intracerebroventricular
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual intracerebroventricular and intravitreal administration (specific dosage and duration not provided)
Trial: 37942666
Drug: Grade IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grade IV titanium (Ti) implants
Trial: 37942793
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (control for anticoagulation hypothesis)
Trial: 37942793
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (control for anti-inflammatory hypothesis)
Trial: 37943221
Drug: Best practice
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best practice alert (BPA) suggesting guideline-recommended MRAs for eligible patients with a serum potassium of <5.0 mEq/L or novel potassium binders for those with a serum potassium of ≥5.0 mEq/L.
Trial: 37943300
Drug: Methylprednisolone (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (250 mg intravenous injection)
Trial: 37943335
Drug: Neuromodulation (noninvasive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuromodulation (noninvasive low-level tragus stimulation) 4 hours twice daily (n=8)
Trial: 37943351
Drug: Neoadjuvant systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant systemic therapy followed by repeat local treatment (thermal ablation and/or surgical resection)
Trial: 37943351
Drug: Repeat local
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat local treatment alone
Trial: 37943557
Drug: General previsit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General previsit preparation tips for control group physicians and patients.
Trial: 37943580
Drug: Unsupervised therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unsupervised therapy with an active rehabilitation robot
Trial: 37943580
Drug: Minimally supervised
RxNorm normalized name: homatropine hydrobromide Ophthalmic Solution [Minims Homatropine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally supervised therapy
Trial: 37943674
Drug: Standard behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard behavioral cessation treatment (ST) + varenicline
Trial: 37943674
Drug: Standard behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard behavioral cessation treatment (ST) + placebo
Trial: 37944025
Drug: Both synthetic
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both synthetic and biological mesh
Trial: 37944528
Drug: Tepotinib (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tepotinib (oral MET inhibitor)
Trial: 39318203
Drug: EuCorVac-19 (ECV-19)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EuCorVac-19 (ECV-19) vaccine
Trial: 37945063
Drug: Bilateral anterior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral anterior quadratus lumborum nerve block with 60 mL ropivacaine 0.375%
Trial: 37945063
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with isotonic saline injections
Trial: 37945284
Drug: Filgotinib (FIL)
RxNorm normalized name: Nilotinib
DrugBank: Filgotinib (DB14845)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Filgotinib (FIL) treatment
Trial: 37945292
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) 1 g/kg/dose, given 24-36 hours apart
Trial: 37945297
Drug: Intravenous ferric
RxNorm normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ferric derisomaltose (500-1000 mg infusion at least 21 days prior to surgery)
Trial: 37945305
Drug: E-Fit intervention
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: E-Fit intervention (multimodal and personalised EF intervention) consisting of computer-based EF training using CogniFit Inc 2022, performed three times a week at home; weekly EF remote strategy coaching and analogue games.
Trial: 37945305
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group following their daily routines and completing a diary about their everyday activities four times a week.
Trial: 37945326
Drug: Secondary cytoreductive
RxNorm normalized name: Secondary potassium phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secondary cytoreductive surgery (SCS) followed by non-platinum single agent chemotherapy (paclitaxel, gemcitabine or liposomal adriamycin) for at least 4 cycles
Trial: 37945326
Drug: Non-platinum single
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-platinum single agent chemotherapy
Trial: 37945413
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion (target effect-site concentrations of 0.5, 1, 2, 3, 4 ng/ml)
Trial: 37945419
Drug: Community pharmacist-led
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community pharmacist-led educational intervention and medication review
Trial: 37946117
Drug: Neurotoxic chemotherapy
RxNorm normalized name: botulinum neurotoxin A immune FAB2
DrugBank: Equine Botulinum Neurotoxin A Immune FAB2 (DB13900)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurotoxic chemotherapy
Trial: 37946117
Drug: Wearable devices
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wearable devices measuring daily gait quality and physical activity
Trial: 37946117
Drug: Weekly electronic
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly electronic surveys for self-reporting symptoms
Trial: 37946136
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy (SBRT)
Trial: 37946136
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of atezolizumab, tiragolumab, and SBRT
Trial: 37946201
Drug: Mid-treatment decreases
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mid-treatment decreases in peak PE from imaging
Trial: 37946201
Drug: Post-treatment decreases
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment decreases in several DCE-MRI measures
Trial: 37946272
Drug: Clear protein
RxNorm normalized name: Caladryl Clear
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clear protein powder shake (200 ml containing 20 g of whey protein) taken daily for the first 6 months after LRYGB.
Trial: 37946283
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin (BV; 1.8 mg/kg) with dacarbazine (DTIC; 375 mg/m2)
Trial: 37946283
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin (BV) with nivolumab (3 mg/kg)
Trial: 37946314
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen (HBO) treatment, one or two sessions
Trial: 37947157
Drug: MK-2206 150
RxNorm normalized name: MK-2206
DrugBank: MK-2206 (DB16828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-2206 150 mg weekly (escalation to 200 mg allowed)
Trial: 37947190
Drug: Bortezomib (BTZ)
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib (BTZ) 1.3 mg/m2 body surface area subcutaneously once weekly for 8 weeks followed by oral cyclophosphamide 1 mg/kg/d for 4 months
Trial: 37947974
Drug: Vacuum-assisted biopsy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vacuum-assisted biopsy (VAB) after neoadjuvant systemic treatment (NAST)
Trial: 37948006
Drug: Galcanezumab 120
RxNorm normalized name: Galcanezumab 120 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galcanezumab 120 mg SC per month (after a 240 mg loading dose)
Trial: 37948006
Drug: Rimegepant 75
RxNorm normalized name: rimegepant 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimegepant 75 mg ODT q.o.d.
Trial: 37948170
Drug: PRISCA (patient-centered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRISCA (patient-centered approach including healthy lifestyle promotion, pharmacological management of CVRFs, psychotropic drug optimization, and motivational follow-up)
Trial: 37948736
Drug: Inhaled Molgramostim
RxNorm normalized name: molgramostim
DrugBank: Molgramostim (DB12525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Molgramostim
Trial: 37948759
Drug: Neutralizing monoclonal
RxNorm normalized name: Dkk1-neutralizing monoclonal antibody dkn-01
DrugBank: Sirexatamab (DB17515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutralizing monoclonal antibodies (nmAbs)
Trial: 37948832
Drug: KW-6356 3
RxNorm normalized name: KW-7158
DrugBank: KW-7158 (DB05498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KW-6356 3 mg/day
Trial: 37948832
Drug: KW-6356 6
RxNorm normalized name: KW-7158
DrugBank: KW-7158 (DB05498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KW-6356 6 mg/day
Trial: 37949617
Drug: TIL treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIL treatment during chemotherapy without IFNa (n=13)
Trial: 37949617
Drug: TIL treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIL treatment with IFNa
Trial: 37949617
Drug: TIL infusions
RxNorm normalized name: CD8 enriched young TIL
DrugBank: CD8+ enriched young tumor infiltrating lymphocytes (DB17460)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIL infusions during platinum-based chemotherapy
Trial: 37949619
Drug: Obstetrics and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obstetrics and gynaecology (O&G) trainees
Trial: 37949619
Drug: Senior obstetrics
RxNorm normalized name: chlorhexidine gluconate Topical Cream [Hibitane Obstetric]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Senior obstetrics and gynaecology (O&G) trainees
Trial: 37949621
Drug: Colchicine 0.6
RxNorm normalized name: colchicine 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 0.6 mg oral daily
Trial: 37949730
Drug: Higher radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher radiation dose (37.5-40 Gy)
Trial: 37949730
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses (32.5 to 40 Gy)
Trial: 37949730
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose levels
Trial: 37950144
Drug: Etripamil (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etripamil (70 mg)
Trial: 37950338
Drug: Amcenestrant 400
RxNorm normalized name: Amcenestrant
DrugBank: SAR-439459 (DB17864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amcenestrant 400 mg
Trial: 37950338
Drug: Amcenestrant 200
RxNorm normalized name: Amcenestrant
DrugBank: SAR-439459 (DB17864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amcenestrant 200 mg
Trial: 37950370
Drug: Cerebrolysin therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrolysin therapy
Trial: 37950392
Drug: Asundexian (10/20/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asundexian (10/20/50 mg daily)
Trial: 37950392
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus standard antiplatelet treatment
Trial: 37950533
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 8-type HPV genotype restriction and VIA
Trial: 37950726
Drug: Etripamil nasal
RxNorm normalized name: etripamil
DrugBank: Etripamil (DB12605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etripamil nasal spray 70 mg
Trial: 37950897
Drug: Aspirin avoidance
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin avoidance
Trial: 37950907
Drug: Self-monitoring with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-monitoring with research physician-optimized antihypertensive titration
Trial: 37950918
Drug: High-sodium diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-sodium diet (approximately 2200 mg sodium added daily to usual diet)
Trial: 37950918
Drug: Low-sodium diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-sodium diet (approximately 500 mg daily total)
Trial: 37950919
Drug: Self-monitoring along
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-monitoring along with physician-optimized antihypertensive titration
Trial: 37951069
Drug: Self-management program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management program based on acceptance and commitment therapy
Trial: 37951218
Drug: Sequential chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemoradiotherapy combined with toripalimab
Trial: 37951245
Drug: Orismilast 20
RxNorm normalized name: Orismilast
DrugBank: Orismilast (DB19042)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orismilast 20 mg
Trial: 37951245
Drug: Orismilast 30
RxNorm normalized name: Orismilast
DrugBank: Orismilast (DB19042)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orismilast 30 mg
Trial: 37951292
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg plus Ezetimibe 10 mg (combination lipid-lowering therapy)
Trial: 37951292
Drug: High-intensity atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity atorvastatin monotherapy
Trial: 37951560
Drug: Standard vedolizumab
RxNorm normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard vedolizumab (300 mg every 8 weeks)
Trial: 37951560
Drug: Dose-optimized vedolizumab
RxNorm normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose-optimized vedolizumab (600 mg at week 6, then 300 mg every 4 weeks or 600 mg at week 6, then 600 mg every 4 weeks)
Trial: 37951560
Drug: Dose-optimized vedolizumab
RxNorm normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose-optimized vedolizumab